---
document_datetime: 2025-11-23 08:05:33
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/imatinib-medac.html
document_name: imatinib-medac.html
version: success
processing_time: 0.1064489
conversion_datetime: 2025-12-26 19:57:04.035952
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Imatinib medac

[RSS](/en/individual-human-medicine.xml/66990)

##### Withdrawn

This medicine's authorisation has been withdrawn

imatinib

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 14 February 2019, the European Commission withdrew the marketing authorisation for Imatinib medac (imatinib) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, medac Gesellschaft fur klinische Spezialpraparate mbH, which notified the European Commission of its decisionto permanently discontinue the marketing of the product for commercial reasons.

Imatinib medac was granted marketing authorisation in the EU on 25 September 2013 for treatment of leukaemia. The marketing authorisation was initially valid for a 5-year period. Imatinib medac was a generic medicine of Glivec for treatment of leukaemia. There are other generic medicinal products of Glivec authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Imatinib medac is updated to indicate that the marketing authorisation is no longer valid.

Imatinib medac : EPAR - Summary for the public

Reference Number: EMA/268384/2015

English (EN) (645.79 KB - PDF)

**First published:** 23/10/2013

**Last updated:** 26/06/2015

[View](/en/documents/overview/imatinib-medac-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-22)

български (BG) (732.95 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

26/06/2015

[View](/bg/documents/overview/imatinib-medac-epar-summary-public_bg.pdf)

español (ES) (645.85 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

26/06/2015

[View](/es/documents/overview/imatinib-medac-epar-summary-public_es.pdf)

čeština (CS) (709.92 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

26/06/2015

[View](/cs/documents/overview/imatinib-medac-epar-summary-public_cs.pdf)

dansk (DA) (646.49 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

26/06/2015

[View](/da/documents/overview/imatinib-medac-epar-summary-public_da.pdf)

Deutsch (DE) (646.71 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

26/06/2015

[View](/de/documents/overview/imatinib-medac-epar-summary-public_de.pdf)

eesti keel (ET) (647.15 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

26/06/2015

[View](/et/documents/overview/imatinib-medac-epar-summary-public_et.pdf)

ελληνικά (EL) (731.71 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

26/06/2015

[View](/el/documents/overview/imatinib-medac-epar-summary-public_el.pdf)

français (FR) (641.98 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

26/06/2015

[View](/fr/documents/overview/imatinib-medac-epar-summary-public_fr.pdf)

hrvatski (HR) (657.5 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

26/06/2015

[View](/hr/documents/overview/imatinib-medac-epar-summary-public_hr.pdf)

italiano (IT) (640.34 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

26/06/2015

[View](/it/documents/overview/imatinib-medac-epar-summary-public_it.pdf)

latviešu valoda (LV) (728.96 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

26/06/2015

[View](/lv/documents/overview/imatinib-medac-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (690.93 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

26/06/2015

[View](/lt/documents/overview/imatinib-medac-epar-summary-public_lt.pdf)

magyar (HU) (704.2 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

26/06/2015

[View](/hu/documents/overview/imatinib-medac-epar-summary-public_hu.pdf)

Malti (MT) (710.17 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

26/06/2015

[View](/mt/documents/overview/imatinib-medac-epar-summary-public_mt.pdf)

Nederlands (NL) (646.06 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

26/06/2015

[View](/nl/documents/overview/imatinib-medac-epar-summary-public_nl.pdf)

polski (PL) (710.5 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

26/06/2015

[View](/pl/documents/overview/imatinib-medac-epar-summary-public_pl.pdf)

português (PT) (642.51 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

26/06/2015

[View](/pt/documents/overview/imatinib-medac-epar-summary-public_pt.pdf)

română (RO) (660.01 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

26/06/2015

[View](/ro/documents/overview/imatinib-medac-epar-summary-public_ro.pdf)

slovenčina (SK) (709.86 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

26/06/2015

[View](/sk/documents/overview/imatinib-medac-epar-summary-public_sk.pdf)

slovenščina (SL) (702.54 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

26/06/2015

[View](/sl/documents/overview/imatinib-medac-epar-summary-public_sl.pdf)

Suomi (FI) (646.31 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

26/06/2015

[View](/fi/documents/overview/imatinib-medac-epar-summary-public_fi.pdf)

svenska (SV) (641.5 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

26/06/2015

[View](/sv/documents/overview/imatinib-medac-epar-summary-public_sv.pdf)

## Product information

Imatinib medac : EPAR - Product Information

English (EN) (1011.81 KB - PDF)

**First published:** 23/10/2013

**Last updated:** 14/05/2018

[View](/en/documents/product-information/imatinib-medac-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-566)

български (BG) (2.26 MB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/bg/documents/product-information/imatinib-medac-epar-product-information_bg.pdf)

español (ES) (941.25 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/es/documents/product-information/imatinib-medac-epar-product-information_es.pdf)

čeština (CS) (1.85 MB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/cs/documents/product-information/imatinib-medac-epar-product-information_cs.pdf)

dansk (DA) (1016.75 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/da/documents/product-information/imatinib-medac-epar-product-information_da.pdf)

Deutsch (DE) (1.32 MB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/de/documents/product-information/imatinib-medac-epar-product-information_de.pdf)

eesti keel (ET) (960.1 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/et/documents/product-information/imatinib-medac-epar-product-information_et.pdf)

ελληνικά (EL) (2.26 MB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/el/documents/product-information/imatinib-medac-epar-product-information_el.pdf)

français (FR) (1.06 MB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/fr/documents/product-information/imatinib-medac-epar-product-information_fr.pdf)

hrvatski (HR) (1.02 MB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/hr/documents/product-information/imatinib-medac-epar-product-information_hr.pdf)

íslenska (IS) (1.01 MB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/is/documents/product-information/imatinib-medac-epar-product-information_is.pdf)

italiano (IT) (1017.88 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/it/documents/product-information/imatinib-medac-epar-product-information_it.pdf)

latviešu valoda (LV) (1.81 MB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/lv/documents/product-information/imatinib-medac-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.05 MB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/lt/documents/product-information/imatinib-medac-epar-product-information_lt.pdf)

magyar (HU) (1.73 MB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/hu/documents/product-information/imatinib-medac-epar-product-information_hu.pdf)

Malti (MT) (1.8 MB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/mt/documents/product-information/imatinib-medac-epar-product-information_mt.pdf)

Nederlands (NL) (1022.38 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/nl/documents/product-information/imatinib-medac-epar-product-information_nl.pdf)

norsk (NO) (1009.64 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/no/documents/product-information/imatinib-medac-epar-product-information_no.pdf)

polski (PL) (1.8 MB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/pl/documents/product-information/imatinib-medac-epar-product-information_pl.pdf)

português (PT) (994.47 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/pt/documents/product-information/imatinib-medac-epar-product-information_pt.pdf)

română (RO) (1.12 MB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/ro/documents/product-information/imatinib-medac-epar-product-information_ro.pdf)

slovenčina (SK) (1.74 MB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/sk/documents/product-information/imatinib-medac-epar-product-information_sk.pdf)

slovenščina (SL) (1.71 MB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/sl/documents/product-information/imatinib-medac-epar-product-information_sl.pdf)

Suomi (FI) (1.27 MB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/fi/documents/product-information/imatinib-medac-epar-product-information_fi.pdf)

svenska (SV) (1008.63 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

14/05/2018

[View](/sv/documents/product-information/imatinib-medac-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0009 11/04/2018

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Imatinib medac : EPAR - All Authorised presentations

English (EN) (593.31 KB - PDF)

**First published:** 23/10/2013

**Last updated:** 23/10/2013

[View](/en/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-810)

български (BG) (616.45 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/bg/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_bg.pdf)

español (ES) (575.28 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/es/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_es.pdf)

čeština (CS) (598.04 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/cs/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (574.72 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/da/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (574.39 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/de/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (575.57 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/et/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (616.71 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/el/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_el.pdf)

français (FR) (575.47 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/fr/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (584.78 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/hr/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (575.29 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/is/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_is.pdf)

italiano (IT) (19.47 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/it/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (609.21 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/lv/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (605.7 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/lt/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (597.42 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/hu/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (603.63 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/mt/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (574.55 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/nl/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (574.35 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/no/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_no.pdf)

polski (PL) (605.1 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/pl/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_pl.pdf)

português (PT) (574.34 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/pt/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_pt.pdf)

română (RO) (588.88 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/ro/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (604.94 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/sk/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (26.43 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/sl/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (576.16 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/fi/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (574.95 KB - PDF)

**First published:**

23/10/2013

**Last updated:**

23/10/2013

[View](/sv/documents/all-authorised-presentations/imatinib-medac-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Imatinib medac Active substance imatinib International non-proprietary name (INN) or common name imatinib Therapeutic area (MeSH)

- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Dermatofibrosarcoma
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Myelodysplastic-Myeloproliferative Diseases
- Hypereosinophilic Syndrome

Anatomical therapeutic chemical (ATC) code L01XE01

### Pharmacotherapeutic group

Protein kinase inhibitors

### Therapeutic indication

Imatinib medac is indicated for the treatment of:

- paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment;
- paediatric patients with Ph+CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase;
- adult and paediatric patients with Ph+CML in blast crisis;
- adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ALL) integrated with chemotherapy;
- adult patients with relapsed or refractory Ph+ALL as monotherapy;
- adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements;
- adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR? rearrangement;
- adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.

The effect of imatinib on the outcome of bone marrow transplantation has not been determined.

In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic DFSP.

The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited. Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.

## Authorisation details

EMA product number EMEA/H/C/002692

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Medac

Gesellschaft fuer Spezialpraeparaten mbH

Marketing authorisation issued 25/09/2013 Withdrawal of marketing authorisation 14/02/2019 Revision 5

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Imatinib medac : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (639.92 KB - PDF)

**First published:** 26/06/2015

**Last updated:** 14/05/2018

[View](/en/documents/procedural-steps-after/imatinib-medac-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Imatinib medac : EPAR - Public assessment report

Adopted

Reference Number: EMA/622006/2013

English (EN) (975.72 KB - PDF)

**First published:** 23/10/2013

**Last updated:** 23/10/2013

[View](/en/documents/assessment-report/imatinib-medac-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Imatinib medac

Adopted

Reference Number: Imatinib medac

English (EN) (710.06 KB - PDF)

**First published:** 05/08/2013

**Last updated:** 05/08/2013

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-imatinib-medac_en.pdf)

**This page was last updated on** 16/10/2019

## Share this page

[Back to top](#main-content)